Literature DB >> 8080497

Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use.

S M Pear1, T H Williamson, K M Bettin, D N Gerding, J N Galgiani.   

Abstract

OBJECTIVE: To report the investigation and effective control of a nosocomial epidemic of Clostridium difficile-associated diarrhea.
DESIGN: Concurrent surveillance for identification of new nosocomial cases, retrospective case-control analysis, and hospital formulary control of antibiotic use.
SETTING: University-affiliated Veterans Affairs Medical Center located in southwestern United States. PATIENTS: Hospitalized patients who developed diarrhea submitted stool specimens for cytotoxin assay. Patients who were positive for cytotoxin were compared with control patients without infection. MEASUREMENTS: Isolates of C. difficile were typed by restriction endonuclease analysis. Antimicrobial agent use from hospital pharmacy records and selected patient data from chart review were correlated with frequency of specific laboratory abnormalities.
RESULTS: For 13 months, the monthly incidence of C. difficile infection averaged more than five times that for the previous 21 months. Stool specimens from 34 patients (59%) contained a single strain (restriction enzyme analysis type J7). Clindamycin was statistically associated with the epidemic as shown by the following: clindamycin use at our center compared with national normal values, clindamycin use for years before compared with during the epidemic, monthly use of clindamycin compared with monthly frequency of infection, frequency of infection in patients receiving clindamycin compared with that in patients receiving other antimicrobial agents, and amount of clindamycin used by infected patients compared with that used by control patients. Restricting clindamycin use led to a prompt disease in infection rate and the type J7 organisms.
CONCLUSION: A nosocomial epidemic of C. difficile diarrhea was controlled by analysis of antibiotic use patterns and by subsequent restriction of clindamycin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080497     DOI: 10.7326/0003-4819-120-4-199402150-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  42 in total

1.  Prevention of healthcare‐associated Clostridium difficile infection: what works?

Authors:  Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital.

Authors:  S K Nath; S Salama; D Persaud; J H Thornley; I Smith; G Foster; C Rotstein
Journal:  Can J Infect Dis       Date:  1994-11

3.  Predictors of Clostridium difficile colitis infections in hospitals.

Authors:  R Ricciardi; K Harriman; N N Baxter; L K Hartman; R J Town; B A Virnig
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

4.  Clostridium difficile: The evolving story.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-11       Impact factor: 2.471

5.  Antibiotic-associated diarrhea in HIV-infected patients receiving clindamycin.

Authors:  H Slevogt; B Ruf
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

Review 6.  The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile.

Authors:  Rossana Rosa; Curtis J Donskey; L Silvia Munoz-Price
Journal:  Curr Infect Dis Rep       Date:  2018-06-07       Impact factor: 3.725

7.  Biogeography of microbial bile acid transformations along the murine gut.

Authors:  Solenne Marion; Lyne Desharnais; Nicolas Studer; Yuan Dong; Matheus D Notter; Suresh Poudel; Laure Menin; Andrew Janowczyk; Robert L Hettich; Siegfried Hapfelmeier; Rizlan Bernier-Latmani
Journal:  J Lipid Res       Date:  2020-07-13       Impact factor: 5.922

Review 8.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

9.  Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county.

Authors:  T Norén; T Akerlund; E Bäck; L Sjöberg; I Persson; I Alriksson; L G Burman
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  Clostridium difficile-associated enteric disease after percutaneous endoscopic gastrostomy.

Authors:  Shiro Yokohama; Masaru Aoshima; Toshiyuki Asama; Junya Shindo; Junichi Maruyama
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.